{"id":384920,"date":"2020-11-19T08:03:24","date_gmt":"2020-11-19T13:03:24","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=384920"},"modified":"2020-11-19T08:03:24","modified_gmt":"2020-11-19T13:03:24","slug":"aspira-womens-health-inc-announces-a-collaborative-agreement-with-baylor-genetics-for-the-co-development-of-an-ovarian-cancer-early-detection-test","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announces-a-collaborative-agreement-with-baylor-genetics-for-the-co-development-of-an-ovarian-cancer-early-detection-test\/","title":{"rendered":"Aspira Women\u2019s Health, Inc. Announces a Collaborative Agreement with Baylor Genetics for the Co-Development of an Ovarian Cancer Early-Detection Test"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">AUSTIN, Texas, Nov.  19, 2020  (GLOBE NEWSWIRE) &#8212; Aspira Women\u2019s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women\u2019s health company, today announced it has entered into a collaborative research agreement with Baylor Genetics (Houston, TX) to co-develop a novel Ovarian Cancer early-detection test. Ovarian cancer accounts for more deaths than any other cancer of the female reproductive system and is the <strong>only gender specific cancer with <\/strong><strong>an over<\/strong><strong> 50 percent mortality rate<\/strong> impacting women of all ages and ethnicities.<\/p>\n<p>\u201cAspira has over 10 years of research and experience in early stage detection of ovarian cancer in women, and we are thrilled to accelerate our innovation and product development platform by entering into this collaborative agreement with Baylor Genetics. We look forward to combining the strengths from each respective research team, and working together on our OVA360 clinical study, specifically in our mutual goal of characterizing an Ovarian Cancer molecular profile,\u201d said Lesley Northrop, Ph.D., FACMG, Chief Scientific Officer at Aspira Women\u2019s Health. \u201cBaylor Genetics is one of the founding institutions of genomic research, collaborating on proteogenomic technology in the development of a cell-free DNA-based Ovarian Cancer risk detection test.\u201d\u00a0\u00a0<\/p>\n<p>Dr. Brian Merritt, Medical Director at Baylor Genetics, said,\u201cOvarian cancer is a particular cancer type in need of better early detection methods, and advances in genetic testing technologies now enable us to develop such a test for clinical use. Aligning with Aspira to co-develop this novel test will advance precision medicine for women with ovarian cancer and potentially lead to earlier intervention, more targeted treatments, and improved outcomes.\u201d<\/p>\n<p>Baylor Genetics has been a leading pioneer in genetic testing, providing unmatched knowledge and experience in hereditary genetics, clinical genomics, and translational technology. Aspira is uniquely positioned to co-develop and recruit patient samples for the development of this new test. With over 10 years of experience in ovarian cancer risk assessment testing and developing multiple FDA-cleared products that are instrumental in helping providers and patients detect risk in women with pelvic masses, Aspira provides both clinical and commercialization expertise for bringing this novel test to market.<\/p>\n<p>\n        <strong>About Aspira Women\u2019s Health Inc.<\/strong><br \/>\n        <br \/>Aspira Women\u2019s Health, Inc. (formerly known as, Vermillion inc.,\u00a0Nasdaq:\u00a0VRML) is transforming women\u2019s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women.\u00a0 ASPIRA is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis.\u00a0OVA1\u00ae\u00a0plus includes our FDA-cleared products, OVA1<sup>\u00ae<\/sup>, and OVERA<sup>\u00ae<\/sup>\u00a0to detect risk of ovarian malignancy in women with adnexal masses. ASPIRA GenetiX<sup>TM<\/sup>\u00a0testing offers both targeted and comprehensive genetic testing options with a gynecologic focus.\u00a0 With over 10 years of expertise in ovarian cancer risk assessment, ASPIRA is delivering a portfolio of pelvic mass products over a patient\u2019s lifetime with our cutting-edge research. The next generation of products in development are OVANEX<sup>TM<\/sup>\u00a0and EndoCheck<sup>TM<\/sup>.\u00a0Visit our website for more information at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Tv8J4zeaVR2-XQQSv6uIrdS_Mnc9uqW0RwvI_IfceBDyMAn_PITvmldTkH73y5T9mo5N_2eNZazYj2bXNDTjUw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.aspirawh.com<\/u><\/a>.<\/p>\n<p>\n        <strong>About Baylor<\/strong><br \/>\n        <strong> Genetics <\/strong><br \/>\n        <br \/>Baylor Genetics is a joint venture of H.U. Group Holdings, Inc. and\u00a0Baylor College of Medicine, including the #1 NIH-funded Department of Molecular and Human Genetics. Located in\u00a0Houston&#8217;s\u00a0Texas Medical Center,\u00a0Baylor Genetics\u00a0serves clients in 50 states and 16 countries.<\/p>\n<p>\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>Ashley R. Robinson <br \/>LifeSci Advisors, LLC <br \/>Tel 617-430-7577<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=idvxeOIPpVr7aMcCUArHljtny3Rdvvp4psABdwsHrpLwhbdFkYnfmD1lXm7d64h5DylajmkBciPjgZadO7MyR3vA9y-McbIcQPqdFwcAWwE=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Arr@lifesciadvisors.com<\/a><\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Jaime Abrusci<br \/>RX Medical Dynamics<br \/>Tel 646-599-8606 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=k5CZUphgJ4PMntirueDCctzYP05g2XVbFCmb9COylInKG39O8jMZ8WS1BOHPx_manNyqRWUJPd0mnh0GpqEYb1bb2WICCO3Eq5ALzdH_aHk=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">jabrusci@rxmedyn.com<\/a><\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODgzNiMzODM0Njc3IzUwMDA0NTYzNw==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/972f10ed-d473-4917-bc8a-c2007a677ff0\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>AUSTIN, Texas, Nov. 19, 2020 (GLOBE NEWSWIRE) &#8212; Aspira Women\u2019s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women\u2019s health company, today announced it has entered into a collaborative research agreement with Baylor Genetics (Houston, TX) to co-develop a novel Ovarian Cancer early-detection test. Ovarian cancer accounts for more deaths than any other cancer of the female reproductive system and is the only gender specific cancer with an over 50 percent mortality rate impacting women of all ages and ethnicities. \u201cAspira has over 10 years of research and experience in early stage detection of ovarian cancer in women, and we are thrilled to accelerate our innovation and product development platform by entering into this collaborative agreement with Baylor Genetics. We look forward &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announces-a-collaborative-agreement-with-baylor-genetics-for-the-co-development-of-an-ovarian-cancer-early-detection-test\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Aspira Women\u2019s Health, Inc. Announces a Collaborative Agreement with Baylor Genetics for the Co-Development of an Ovarian Cancer Early-Detection Test&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-384920","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aspira Women\u2019s Health, Inc. Announces a Collaborative Agreement with Baylor Genetics for the Co-Development of an Ovarian Cancer Early-Detection Test - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announces-a-collaborative-agreement-with-baylor-genetics-for-the-co-development-of-an-ovarian-cancer-early-detection-test\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aspira Women\u2019s Health, Inc. Announces a Collaborative Agreement with Baylor Genetics for the Co-Development of an Ovarian Cancer Early-Detection Test - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AUSTIN, Texas, Nov. 19, 2020 (GLOBE NEWSWIRE) &#8212; Aspira Women\u2019s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women\u2019s health company, today announced it has entered into a collaborative research agreement with Baylor Genetics (Houston, TX) to co-develop a novel Ovarian Cancer early-detection test. Ovarian cancer accounts for more deaths than any other cancer of the female reproductive system and is the only gender specific cancer with an over 50 percent mortality rate impacting women of all ages and ethnicities. \u201cAspira has over 10 years of research and experience in early stage detection of ovarian cancer in women, and we are thrilled to accelerate our innovation and product development platform by entering into this collaborative agreement with Baylor Genetics. We look forward &hellip; Continue reading &quot;Aspira Women\u2019s Health, Inc. Announces a Collaborative Agreement with Baylor Genetics for the Co-Development of an Ovarian Cancer Early-Detection Test&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announces-a-collaborative-agreement-with-baylor-genetics-for-the-co-development-of-an-ovarian-cancer-early-detection-test\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-19T13:03:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODgzNiMzODM0Njc3IzUwMDA0NTYzNw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-announces-a-collaborative-agreement-with-baylor-genetics-for-the-co-development-of-an-ovarian-cancer-early-detection-test\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-announces-a-collaborative-agreement-with-baylor-genetics-for-the-co-development-of-an-ovarian-cancer-early-detection-test\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aspira Women\u2019s Health, Inc. Announces a Collaborative Agreement with Baylor Genetics for the Co-Development of an Ovarian Cancer Early-Detection Test\",\"datePublished\":\"2020-11-19T13:03:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-announces-a-collaborative-agreement-with-baylor-genetics-for-the-co-development-of-an-ovarian-cancer-early-detection-test\\\/\"},\"wordCount\":596,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-announces-a-collaborative-agreement-with-baylor-genetics-for-the-co-development-of-an-ovarian-cancer-early-detection-test\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODgzNiMzODM0Njc3IzUwMDA0NTYzNw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-announces-a-collaborative-agreement-with-baylor-genetics-for-the-co-development-of-an-ovarian-cancer-early-detection-test\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-announces-a-collaborative-agreement-with-baylor-genetics-for-the-co-development-of-an-ovarian-cancer-early-detection-test\\\/\",\"name\":\"Aspira Women\u2019s Health, Inc. Announces a Collaborative Agreement with Baylor Genetics for the Co-Development of an Ovarian Cancer Early-Detection Test - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-announces-a-collaborative-agreement-with-baylor-genetics-for-the-co-development-of-an-ovarian-cancer-early-detection-test\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-announces-a-collaborative-agreement-with-baylor-genetics-for-the-co-development-of-an-ovarian-cancer-early-detection-test\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODgzNiMzODM0Njc3IzUwMDA0NTYzNw==\",\"datePublished\":\"2020-11-19T13:03:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-announces-a-collaborative-agreement-with-baylor-genetics-for-the-co-development-of-an-ovarian-cancer-early-detection-test\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-announces-a-collaborative-agreement-with-baylor-genetics-for-the-co-development-of-an-ovarian-cancer-early-detection-test\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-announces-a-collaborative-agreement-with-baylor-genetics-for-the-co-development-of-an-ovarian-cancer-early-detection-test\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODgzNiMzODM0Njc3IzUwMDA0NTYzNw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODgzNiMzODM0Njc3IzUwMDA0NTYzNw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-announces-a-collaborative-agreement-with-baylor-genetics-for-the-co-development-of-an-ovarian-cancer-early-detection-test\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aspira Women\u2019s Health, Inc. Announces a Collaborative Agreement with Baylor Genetics for the Co-Development of an Ovarian Cancer Early-Detection Test\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aspira Women\u2019s Health, Inc. Announces a Collaborative Agreement with Baylor Genetics for the Co-Development of an Ovarian Cancer Early-Detection Test - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announces-a-collaborative-agreement-with-baylor-genetics-for-the-co-development-of-an-ovarian-cancer-early-detection-test\/","og_locale":"en_US","og_type":"article","og_title":"Aspira Women\u2019s Health, Inc. Announces a Collaborative Agreement with Baylor Genetics for the Co-Development of an Ovarian Cancer Early-Detection Test - Market Newsdesk","og_description":"AUSTIN, Texas, Nov. 19, 2020 (GLOBE NEWSWIRE) &#8212; Aspira Women\u2019s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women\u2019s health company, today announced it has entered into a collaborative research agreement with Baylor Genetics (Houston, TX) to co-develop a novel Ovarian Cancer early-detection test. Ovarian cancer accounts for more deaths than any other cancer of the female reproductive system and is the only gender specific cancer with an over 50 percent mortality rate impacting women of all ages and ethnicities. \u201cAspira has over 10 years of research and experience in early stage detection of ovarian cancer in women, and we are thrilled to accelerate our innovation and product development platform by entering into this collaborative agreement with Baylor Genetics. We look forward &hellip; Continue reading \"Aspira Women\u2019s Health, Inc. Announces a Collaborative Agreement with Baylor Genetics for the Co-Development of an Ovarian Cancer Early-Detection Test\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announces-a-collaborative-agreement-with-baylor-genetics-for-the-co-development-of-an-ovarian-cancer-early-detection-test\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-19T13:03:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODgzNiMzODM0Njc3IzUwMDA0NTYzNw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announces-a-collaborative-agreement-with-baylor-genetics-for-the-co-development-of-an-ovarian-cancer-early-detection-test\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announces-a-collaborative-agreement-with-baylor-genetics-for-the-co-development-of-an-ovarian-cancer-early-detection-test\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aspira Women\u2019s Health, Inc. Announces a Collaborative Agreement with Baylor Genetics for the Co-Development of an Ovarian Cancer Early-Detection Test","datePublished":"2020-11-19T13:03:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announces-a-collaborative-agreement-with-baylor-genetics-for-the-co-development-of-an-ovarian-cancer-early-detection-test\/"},"wordCount":596,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announces-a-collaborative-agreement-with-baylor-genetics-for-the-co-development-of-an-ovarian-cancer-early-detection-test\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODgzNiMzODM0Njc3IzUwMDA0NTYzNw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announces-a-collaborative-agreement-with-baylor-genetics-for-the-co-development-of-an-ovarian-cancer-early-detection-test\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announces-a-collaborative-agreement-with-baylor-genetics-for-the-co-development-of-an-ovarian-cancer-early-detection-test\/","name":"Aspira Women\u2019s Health, Inc. Announces a Collaborative Agreement with Baylor Genetics for the Co-Development of an Ovarian Cancer Early-Detection Test - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announces-a-collaborative-agreement-with-baylor-genetics-for-the-co-development-of-an-ovarian-cancer-early-detection-test\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announces-a-collaborative-agreement-with-baylor-genetics-for-the-co-development-of-an-ovarian-cancer-early-detection-test\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODgzNiMzODM0Njc3IzUwMDA0NTYzNw==","datePublished":"2020-11-19T13:03:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announces-a-collaborative-agreement-with-baylor-genetics-for-the-co-development-of-an-ovarian-cancer-early-detection-test\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announces-a-collaborative-agreement-with-baylor-genetics-for-the-co-development-of-an-ovarian-cancer-early-detection-test\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announces-a-collaborative-agreement-with-baylor-genetics-for-the-co-development-of-an-ovarian-cancer-early-detection-test\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODgzNiMzODM0Njc3IzUwMDA0NTYzNw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODgzNiMzODM0Njc3IzUwMDA0NTYzNw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announces-a-collaborative-agreement-with-baylor-genetics-for-the-co-development-of-an-ovarian-cancer-early-detection-test\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aspira Women\u2019s Health, Inc. Announces a Collaborative Agreement with Baylor Genetics for the Co-Development of an Ovarian Cancer Early-Detection Test"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/384920","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=384920"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/384920\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=384920"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=384920"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=384920"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}